Introduction:
The global pharmaceutical industry is constantly evolving, with biologics and biosimilars playing a significant role in driving innovation and growth. As patent expiries approach, it is crucial for industry professionals to stay informed about the top players in the market. According to recent data, the global biologics market is expected to reach $400 billion by 2026, with biosimilars accounting for a growing share of this market.
Discover Top 10 Biologics & Biosimilars Patent Expiry Forecasts 2026
1. Humira by AbbVie Inc.
– Humira is one of the top-selling biologic drugs globally, with a market share of 20%.
– With its patent set to expire in 2023, biosimilar competition is expected to increase significantly.
2. Remicade by Johnson & Johnson
– Remicade has been a leading biologic for treating autoimmune diseases, with a production volume of 1.5 million units per year.
– As biosimilars enter the market, Johnson & Johnson faces challenges in maintaining its market share.
3. Rituxan by Roche
– Rituxan is a key biologic in Roche’s portfolio, generating $7 billion in sales annually.
– Patent expiry in 2024 will lead to increased competition from biosimilar manufacturers.
4. Enbrel by Amgen
– Enbrel is a popular biologic used to treat rheumatoid arthritis, with a market share of 15%.
– Amgen is exploring strategies to retain market dominance post-patent expiry in 2025.
5. Herceptin by Roche
– Herceptin is a widely used biologic for breast cancer treatment, with annual sales exceeding $6 billion.
– Roche is focusing on developing new biologics to offset revenue loss from patent expiries.
6. Avastin by Roche
– Avastin is a key biologic for treating various cancers, with a production volume of 2 million units per year.
– Roche is investing in biosimilar development to maintain market leadership.
7. Lantus by Sanofi
– Lantus is a top-selling insulin biologic, with a market share of 25%.
– Sanofi is facing biosimilar competition as Lantus’s patent nears expiry in 2026.
8. Neulasta by Amgen
– Neulasta is a leading biologic for managing chemotherapy-induced neutropenia, with annual sales of $4 billion.
– Amgen is diversifying its biologics portfolio to mitigate revenue risks from patent expiries.
9. Epogen by Amgen
– Epogen is a widely used biologic for treating anemia, with a production volume of 1.2 million units per year.
– Amgen is exploring biosimilar partnerships to expand its market presence.
10. Keytruda by Merck & Co.
– Keytruda is a promising biologic for cancer immunotherapy, with a market share of 10%.
– Merck & Co. is investing in research and development to extend Keytruda’s patent life beyond 2026.
Insights:
As the biologics and biosimilars market continues to grow, patent expiries present both challenges and opportunities for industry players. Biosimilar competition is expected to intensify, leading to price erosion and market share shifts. Companies will need to focus on innovation, strategic partnerships, and portfolio diversification to maintain their competitive edge. By anticipating patent expiry forecasts and adapting to market dynamics, pharmaceutical companies can navigate the evolving landscape and drive sustainable growth in the biologics market.
Related Analysis: View Previous Industry Report
